RxDoctor Payments Data

Ellen Conn, APRN

Family · Bartlesville, OKNPI 1881217719

Payments from drug & device makers

$1,604in general payments, 2019–2025

Across 93 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$410
  • Lilly USA, LLC$244
  • Pfizer$240
  • Amgen$131
  • AbbVie$126
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$70
  • plus $383 from 14 others

What the payments were for

  • Food & beverage$1,604100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,604 in reported general payments places this provider in the 75th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$6,712
Medicare patients
73
Services billed
1,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$52,960
MounjaroTirzepatide34$36,389
EliquisApixaban33$33,924
FarxigaDapagliflozin Propanediol28$24,816
JardianceEmpagliflozin24$21,415
Tresiba Flextouch U-100Insulin Degludec11$8,983
Tresiba Flextouch U-200Insulin Degludec12$8,064
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$7,187
LinzessLinaclotide12$7,159
Atorvastatin Calcium158$2,761
Gabapentin109$1,752
Albuterol Sulfate HfaAlbuterol Sulfate84$1,671
Omeprazole99$1,581
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,576
Levothyroxine Sodium162$1,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$410$52,96048 claims
Lilly USA, LLCMounjaro$244$36,38934 claims
PfizerEliquis$240$33,92433 claims
AstraZenecaFarxiga$52$24,81628 claims
Boehringer IngelheimJardiance$35$21,41524 claims
AbbVieLinzess$126$7,15912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,026 family providers in Oklahoma.

Other family in Bartlesville

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →